Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial

APACT Investigators

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Fingerprint

Dive into the research topics of 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences